Latest News

STAT Plus: 6 burning questions about the Senate Finance Committee’s ambitious new drug pricing plan

WASHINGTON — The Senate Finance Committee’s new bipartisan drug pricing package has the potential to change Medicare more dramatically than almost any piece of health care policy in the last 20 years. But with that big of an overhaul comes even bigger questions.

The package, which was unveiled Tuesday, fundamentally reworks the complicated scheme used to split Medicare drug costs between the government, patients, insurers, and drug makers. It caps how much Medicare patients can pay out of pocket for drugs each year, and it imposes strict limits on how much drug makers can hike their prices.

Continue to STAT Plus to read the full story…

Source link

Related posts

Opinion: Covid-19 and remdesivir: rethinking how we measure a drug’s ‘value’


Study: Fertility Drugs Don’t Raise Ovarian Cancer Risk


GOP’s latest campaign punch on health care relies on classic hook: Medicare


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World